09.27.26 -- Can siRNA Therapies Offer Better Results In Obesity?

On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s.

The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.

Part 2 follows the consequences into Wall Street, asking what better evidence could mean for pharmaceutical valuations and, ultimately, drugs already in the portfolio.

Explore the tax reporting requirements, including the threshold for payments requiring a 1099 form rising from $600 to $2,000 in 2026.

To preserve the quality of care and build a more effective approach to trial design, a sponsor must consider their approach to patient recruitment and enrollment early and often.

Discover how a platform approach to AAV manufacturing can reduce development time and cost, as well as how optimized processes enable reliable production and scalable implementation in bioreactors.

ADC formulation development requires a molecule-specific strategy, balancing antibody, linker, and payload interactions while addressing stability challenges beyond traditional mAb development experience.

Uncover the implications of the shift to the European Medicines Agency's Pharmacovigilance System Master File (PMS) database for the pharmaceutical industry.

In 2024, the number of industry-sponsored clinical trials reaching completion accelerated significantly. Explore the trial counts and rankings, top 5 diseases for trials, and more.

See how AI can be safely and effectively deployed in regulated pharma environments, with practical guidance on risk, governance, and lifecycle management rooted in GAMP 5 principles.